Neurocrine Biosciences, Inc.
HealthcareNASDAQ:NBIX · NASDAQ Global Select
-$2.95 today
Vol 1.05M · Avg 1.17M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$3.1B of revenue converted into $668.6M of net income for the selected period. Gross margin is 98.2% and net margin is 21.3%, showing how much revenue survives after costs and taxes. EPS is $6.49, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.9B +21.4% | $2.4B +24.8% | $1.9B +26.8% | $1.5B +31.3% | $1.1B | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $52.1M +53.2% | $34.0M -14.4% | $39.7M +71.1% | $23.2M +62.2% | $14.3M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $2.8B +21.0% | $2.3B +25.7% | $1.8B +26.1% | $1.5B +30.9% | $1.1B | $8.9B | $7.6B | $6.2B |
| Gross Margin | 98.2% -0.4pp | 98.6% +0.7pp | 97.9% -0.5pp | 98.4% -0.3pp | 98.7% | 9.8% | 28.9% | 38.3% |
| Research & Development | $1.0B +38.9% | $731.1M +29.4% | $565.0M +21.8% | $463.8M +41.4% | $328.1M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $1.2B +14.8% | $1.0B +13.5% | $887.6M +17.9% | $752.7M +29.0% | $583.3M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $2.2B +25.0% | $1.8B +9.7% | $1.6B +31.2% | $1.2B +19.7% | $1.0B | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $30.1M +11.1% | $27.1M +27.2% | $21.3M +36.5% | $15.6M +43.1% | $10.9M | $374.2M | $1.2B | $631.8M |
| EBITDA | $666.6M +4.2% | $639.7M +53.7% | $416.1M +75.9% | $236.6M +71.3% | $138.1M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 23.3% -3.9pp | 27.2% +5.1pp | 22.0% +6.2pp | 15.9% +3.7pp | 12.2% | 5.6% | 46.3% | 42.0% |
| Operating Income | $619.1M +8.5% | $570.5M +127.4% | $250.9M +0.8% | $249.0M +142.9% | $102.5M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 21.6% -2.6pp | 24.2% +10.9pp | 13.3% -3.4pp | 16.7% +7.7pp | 9.0% | 16.6% | 24.1% | 22.0% |
| Interest Income | $90.3M -0.8% | $91.0M | $0 -100.0% | $11.2M | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 -100.0% | $126.6M +2652.2% | $4.6M -35.2% | $7.1M -72.5% | $25.8M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $86.3M +202.1% | -$84.5M -204.1% | $81.2M +331.3% | -$35.1M -3090.9% | -$1.1M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $705.4M +45.1% | $486.0M +46.3% | $332.1M +55.3% | $213.9M +110.9% | $101.4M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 24.7% +4.0pp | 20.6% +3.0pp | 17.6% +3.2pp | 14.4% +5.4pp | 8.9% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $226.8M +56.7% | $144.7M +75.6% | $82.4M +38.7% | $59.4M +403.4% | $11.8M | $1.3B | -$1.6B | $745.2M |
| Net Income | $478.6M +40.2% | $341.3M +36.7% | $249.7M +61.6% | $154.5M +72.4% | $89.6M | $4.9B | $4.8B | $4.7B |
| Net Margin | 16.7% +2.2pp | 14.5% +1.3pp | 13.2% +2.9pp | 10.4% +2.5pp | 7.9% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $5 +41.5% | $3 +32.8% | $3 +59.0% | $2 +69.5% | $1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $5 +41.9% | $3 +33.2% | $2 +58.3% | $2 +69.6% | $1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $99.5M -0.9% | $100.4M +2.8% | $97.7M +2.0% | $95.8M +1.3% | $94.6M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $102.5M -1.2% | $103.7M +2.7% | $101.0M +2.1% | $98.9M +1.0% | $97.9M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Viatris Inc.
NASDAQ:VTRS
$19.19B
Hologic, Inc.
HOLX
$16.97B
The Cooper Companies, Inc.
NASDAQ:COO
$13.24B
Smith & Nephew plc
NYSE:SNN
$12.97B
Elanco Animal Health Incorporated
NYSE:ELAN
$12.07B
ICON Public Limited Company
NASDAQ:ICLR
$11.19B
Dr. Reddy's Laboratories Limited
NYSE:RDY
$11.07B
Summit Therapeutics Inc.
NASDAQ:SMMT
$10.86B
Universal Health Services, Inc.
NYSE:UHS
$9.17B
Tempus AI, Inc.
NASDAQ:TEM
$8.35B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does NBIX generate?
Neurocrine Biosciences, Inc. (NBIX) reported $2.86B of revenue in fiscal 2025.
Is NBIX profitable?
Neurocrine Biosciences, Inc. (NBIX) reported $478.60M of net income, with a net margin of 16.7%.
Explore More
Continue the stock analysis
Jump to another research area for this company.